103 related articles for article (PubMed ID: 20662847)
81. Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab.
Chen A; Hwang TN; Phan LT; McCulley TJ; Yoon MK
Middle East Afr J Ophthalmol; 2012 Oct; 19(4):432-5. PubMed ID: 23248552
[TBL] [Abstract][Full Text] [Related]
82. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
Witzig TE; Inwards DJ; Habermann TM; Dogan A; Kurtin PJ; Gross JB; Ananthamurthy A; Ristow KM; Garity JA
Mayo Clin Proc; 2007 Jun; 82(6):692-9. PubMed ID: 17550749
[TBL] [Abstract][Full Text] [Related]
83. Radiotherapy of lymphoproliferative diseases of the orbit. Surveillance of 65 cases.
Keleti D; Flickinger JC; Hobson SR; Mittal BB
Am J Clin Oncol; 1992 Oct; 15(5):422-7. PubMed ID: 1524043
[TBL] [Abstract][Full Text] [Related]
84. Treatment of benign lymphoid hyperplasia of the orbit with rituximab.
Ho HH; Savar A; Samaniego F; Manning J; Kasyan A; Pro B; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2010; 26(1):11-3. PubMed ID: 20090476
[TBL] [Abstract][Full Text] [Related]
85. Radiotherapy of lymphoid diseases of the orbit.
Austin-Seymour MM; Donaldson SS; Egbert PR; McDougall IR; Kriss JP
Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):371-9. PubMed ID: 3918966
[TBL] [Abstract][Full Text] [Related]
86. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders.
Musto P; D'Auria F
Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115
[TBL] [Abstract][Full Text] [Related]
87. Orbital lymphoproliferative disorders.
Garner A
Br J Ophthalmol; 1992 Jan; 76(1):47-8. PubMed ID: 1739692
[No Abstract] [Full Text] [Related]
88. Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients.
Kojima M; Motoori T; Asano S; Nakamura S
Pathol Res Pract; 2007; 203(6):423-31. PubMed ID: 17540509
[TBL] [Abstract][Full Text] [Related]
89. Lymphoproliferative Disease of the Orbit.
Li EY; Yuen HK; Cheuk W
Asia Pac J Ophthalmol (Phila); 2015; 4(2):106-11. PubMed ID: 26065355
[TBL] [Abstract][Full Text] [Related]
90. Novel therapeutic option for orbital atypical lymphoid hyperplasia.
Talaulikar D; Tridgell D; Leong D; Dahlstrom JE; Cherian M; Prosser I; Sunderland K
Clin Exp Ophthalmol; 2010 Dec; 38(9):892-4. PubMed ID: 20662847
[TBL] [Abstract][Full Text] [Related]
91. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
Shome D; Esmaeli B
Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
[TBL] [Abstract][Full Text] [Related]
92.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
93.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
94.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
95.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
96.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
